Thymidylate synthase · SINGLE PROTEIN · Candida albicans
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Thymidylate synthase shows approved-linked disease relevance led by candidiasis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P12461. Start with candidiasis, then reuse UniProt P12461 as the stable protein anchor across project notes and exports.
Start with candidiasis, then reuse UniProt P12461 as the stable protein anchor across project notes and exports.
Thymidylate synthase shows approved-linked disease relevance led by candidiasis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with candidiasis because it currently carries approved-linked support. Linked drugs include FLUCYTOSINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyThymidylate synthase
Review this target as Thymidylate synthase, mapped to UniProt P12461. Sequence length is 315 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Thymidylate synthase as ChEMBL target CHEMBL2364680, mapped to UniProt P12461. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Thymidylate synthase is the right protein anchor across sources, using UniProt P12461 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why candidiasis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Thymidylate synthase |
| Target Type | SINGLE PROTEIN |
| Organism | Candida albicans |
| UniProt | P12461 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Thymidylate synthase |
| UniProt Accession | P12461 |
| Component Type | Protein |
| Sequence Length | 315 aa |
Thymidylate synthase
Review this target as Thymidylate synthase, mapped to UniProt P12461. Sequence length is 315 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Thymidylate synthase shows approved-linked disease relevance led by candidiasis. 5 more disease programs remain visible in the same review block.
Start review with candidiasis because it currently carries approved-linked support. Linked drugs include FLUCYTOSINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.